Arcutis Biotherapeutics 주식 (NASDAQ: ARQT)

에 대한 최신 뉴스 Arcutis Biotherapeutics (NASDAQ:ARQT) 주식

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Lucid EV. Photo by Around the World Photos on Shutterstock

Equities

Mid Cap

News

Movers

Tech

ARQT

CELH

CPRX

DGNX

GLNG

LCID

SBSW

STNE

지난 일주일 동안 가장 실적이 좋았던 중형주 10개 종목은 다음과 같다. 디지넥스, 넥스트데케이드, 셀시우스, 시그넷 주얼러스, 뉴 포트리스, 밀로즈, 아커티스, 루시드, 캐털리스트, 스톤코

셀시우스·루시드·시그넷 등 지난주 급등한 중형주 10종목 (3월 17일~21일)

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

UBS analyst Roger Boyd maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Buy and lowers the price target from $47 to $40.

Price Target

Analyst Ratings

TENB

UBS Maintains Buy on Tenable Holdings, Lowers Price Target to $40

WIIM

USAR

USA Rare Earth shares are trading lower after the company announced a $75 million PIPE investment.

BMO Capital analyst Brian Pitz maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Outperform and raises the price target from $5000 to $5700.

BKNG

BMO Capital Maintains Outperform on Booking Holdings, Raises Price Target to $5700

UBS analyst Mark Carden maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Buy and lowers the price target from $86 to $83.

UBS Maintains Buy on Sysco, Lowers Price Target to $83

JMP Securities analyst David Scharf reiterates Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Market Outperform and maintains $135 price target.

Reiteration

ENVA

JMP Securities Reiterates Market Outperform on Enova International, Maintains $135 Price Target

Baird analyst William Power maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Outperform and lowers the price target from $160 to $130.

TWLO

Baird Maintains Outperform on Twilio, Lowers Price Target to $130

ETWO

E2open Parent Holdings shares are trading lower after the company reported worse-than-expected Q4 sales results. Also, UBS maintained a Neutral rating on the stock and cut its price target from $3 to $2.5.

Baird analyst Shrenik Kothari maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Outperform and lowers the price target from $44 to $40.

Baird Maintains Outperform on Tenable Holdings, Lowers Price Target to $40

RBBN

Ribbon Communications shares are trading lower after the company reported worse-than-expected Q1 financial results.

UBS analyst Trung Huynh maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and lowers the price target from $768 to $633.

REGN

UBS Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $633

Global Industrial shares are trading higher after the company reported better-than-expected Q1 financial results.

SHEN

Shenandoah Telecommunications shares are trading lower after the company reported worse-than-expected Q1 financial results.

UBS analyst Timothy Chiodo maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Neutral and lowers the price target from $88 to $75.

PYPL

UBS Maintains Neutral on PayPal Holdings, Lowers Price Target to $75

SIMO

Silicon Motion Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

Baird analyst Jeffrey Meuler maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Outperform and lowers the price target from $616 to $589.

SPGI

Baird Maintains Outperform on S&P Global, Lowers Price Target to $589

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 4.003M Barrel Draw Vs 1.080M Barrel Draw Est.; 4.476M Barrel Draw Prior

WERN

Werner Enterprises shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, Evercore ISI Group downgraded the stock from In-Line to Underperform and lowered its price target from $27 to $21.

TACOU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

USA EIA Weekly Distillates Stocks 0.937M Barrel Build Vs 1.710M Barrel Draw Est.; 2.353M Barrel Draw Prior

Macro Notification

General

USA Crude Oil Inventories 2.696M Barrel Draw Vs 0.390M Barrel Build Est.; 0.244M Barrel Build Prior

Health Care

Press Releases

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Legal

Arcutis and Padagis Agree to Stay Patent Lawsuit

Management

Arcutis Announces Chief Financial Officer Transition

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Needham

HC Wainwright & Co.

Jefferies

Goldman Sachs

Mizuho

지난 일주일 동안 가장 실적이 좋았던 중형주 10개 종목은 다음과 같다.
<ol>
<li>디지넥스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>): 주가가 108.29% 급등했다. 이는 투자자 불확실성 및 여러 리스크 요인으로 인해 지난주 시장이 조정 국면에 들어간 후 전반적인 반등이 있었기 때문일 가능성이 높다.</li>
<li>넥스트데케이드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>): 주가가 25.07% 상승했다. 미국 D.C. 항소법원이 2024년 8월 판결에 대한 수정을 발표하여 연방 에너지 규제 위원회의 명령에 대한 무효화 위험을 제거했다.</li>
<li>셀시우스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>): 주가가 21.60% 상승했다. 이는 펩시코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)가 프리바이오틱 <a href="https://www.benzinga.com//node/44360669" target="_blank" rel="noreferrer noopener">소다 브랜드 팝피(Poppi)를 19억 5천만 달러에 인수한다는 소식</a>에 반응했을 가능성이 높다.</li>
<li>시그넷 주얼러스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>): 주가가 21.08% 상승했다. 이는 2025회계연도 4분기 실적을 발표하고 여러 애널리스트가 <a href="https://www.benzinga.com//node/44423649" target="_blank" rel="noreferrer noopener">주가 전망을 수정한</a> 후 발생한 일이다.</li>
<li>뉴 포트리스 에너지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>): 주가가 20.63% 상승했다. 이는 달러 약세와 미국의 후티 공격 목표에 대한 공습으로 인한 영향, 그리고 강한 중국 경제 데이터가 수요 전망을 끌어올렸기 때문이다.</li>
<li>밀로즈 프로퍼티스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>): 주가가 16.61% 상승했다. 이러한 급등은 회사가 첫 배당금을 선언하고 <a href="https://www.benzinga.com//node/44365712" target="_blank" rel="noreferrer noopener">2025년 전망을 발표</a>한 이후 발생했다.</li>
<li>아커티스 바이오테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>): 주가가 16.35% 상승했다. 이는 캐나다 보건부가 아토피성 피부염 치료를 위한 조리브(Zoryve) 크림을 승인한 후 발생한 일이다.</li>
<li>루시드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>): 주가가 15.79% 상승했다. 이는 모건스탠리가 주식을 <a href="https://www.benzinga.com//node/44373086" target="_blank" rel="noreferrer noopener">비중축소에서 중립으로 상향 조정</a>한 이후 발생한 일이다.</li>
<li>캐털리스트 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>): 주가가 15.27% 상승했다.</li>
<li>스톤코 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>): 주가가 14.20% 상승했다. 이는 회사가 4분기 EPS 및 매출이 예상보다 좋게 나타났다고 발표한 후 나타났다.</li>
</ol>
사진 출처: Around the World Photos, Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Arcutis Biotherapeutics

뉴스

에 대한 최신 뉴스 Arcutis Biotherapeutics (NASDAQ:ARQT) 주식

일요일, 3월 23, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌